Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Bioinvent International AB
Rana, Norway
A
1-10 Employees
2018
Key takeaway
BioInvent is focused on developing innovative antibody-based immunotherapies for cancer, particularly targeting hematological cancers and solid tumors. Their unique pipeline and expertise in immunology and antibody biology position them well in the expanding market for cancer immunotherapies.
Reference
Product
Technology | BioInvent
Thelper
Oslo, Norway
A
1-10 Employees
2019
Key takeaway
Thelper AS is developing innovative bispecific antibodies targeting viral antigens expressed in tumors but absent in healthy tissue. Their approach aims to create first-in-class immunotherapies that reduce toxicity for patients with solid tumors.
Reference
Core business
Thelper AS
Diatec Monoclonals AS
Oslo, Norway
A
51-100 Employees
1988
Key takeaway
Curida Diatec is a biotechnology company with over 25 years of experience in antibody production, including monoclonal antibodies. Their expertise and commitment to quality suggest they could be a valuable resource for those interested in bispecific antibodies.
Reference
Service
Services - Curida Diatec
Diatec Monoclonals has over 25 years of experience in the production of monoclonal antibodies. Our customers range from academic research departments and startups to global diagnostics and pharmaceutical companies. Antibody production Mouse, rat, human, rabbit and CHO Small & large scale, 25 mg to 100 g batches Cell line optimisation Recloning and optimisation of cell lines […]
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
BerGenBio
Bergen, Norway
A
11-50 Employees
2007
Key takeaway
BerGenBio is focused on developing innovative drugs for aggressive diseases, particularly through its pipeline of selective AXL inhibitors. Notably, the company has entered a licensing agreement with ADC Therapeutics to develop an AXL-ADC, highlighting its commitment to advancing targeted therapies.
Reference
Core business
Partnering - BerGenBio
Bionor Pharma
Oslo, Norway
A
11-50 Employees
1993
Key takeaway
Bionor Holding AS is focused on developing therapeutic vaccines for a functional cure for HIV, utilizing a combination strategy that may be relevant for bispecific antibody approaches. Their product pipeline includes Vacc-4x, Vacc-C5, and CRX, which targets the prevention of binding between viral components and key immune receptors.
Reference
Product
About CRX - Bionor Holding AS
This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors.
ClexBio
Oslo, Norway
A
1-10 Employees
2020
Key takeaway
ClexBio is a pre-clinical stage regenerative medicine company focused on innovative tissue engineering solutions. Their proprietary technology platform enables scalable tissue generation, which may have implications for advancements in bispecific antibody development.
Reference
Core business
ClexBio | Engineering Human Tissue Transplants
ClexBio is a biotech company creating innovative solutions for tissue engineering and single-cell techniques using advanced microfluidics and the proprietary CLEX hydrogel technology.
NEC OncoImmunity AS
Oslo, Norway
A
11-50 Employees
2014
Key takeaway
NEC OncoImmunity AS is an AI-driven biotech company that focuses on personalized cancer immunotherapy by predicting immunogenic antigens. Their innovative software solutions aim to enhance the discovery of neoantigen-based therapies.
Reference
Core business
NEC OncoImmunity AS
EXACT THERAPEUTICS AS
Oslo, Norway
A
1-10 Employees
2012
Key takeaway
EXACT Therapeutics AS is a clinical-stage biopharmaceutical company focused on enhancing therapeutic delivery through its Acoustic Cluster Therapy (ACT®) platform. This innovative approach has applications in oncology, including chemotherapy and immunotherapy, by enabling precise delivery of treatments directly into tumors and across the blood-brain barrier.
Reference
Core business
Company — EXACT THERAPEUTICS
Biolink Group
Sandnes, Norway
A
1-10 Employees
1998
Key takeaway
Biolink Group focuses on developing innovative applications based on biologically active compounds, showcasing its expertise in biotech research and development since the 1980s.
Reference
Core business
Biolink Group - Home
MIM PHARMA
Oslo, Norway
A
11-50 Employees
2013
Key takeaway
MIM Pharma is a science-driven organization focused on developing innovative medical solutions, including a natural plant-based antiviral and immune-enhancing treatment for COVID-19 and influenza. Their research team employs advanced technologies and methodologies to rapidly address emerging viruses, highlighting their commitment to improving human health through continuous innovation.
Reference
Core business
MIM PHARMA
Technologies which have been searched by others and may be interesting for you:
When exploring the bispecific antibody industry in Norway, several key considerations come into play. The regulatory landscape is crucial, as Norway adheres to European Medicines Agency (EMA) standards, which can influence approval processes and compliance requirements for bispecific antibodies. Companies need to navigate stringent regulations regarding clinical trials and product safety, which may present challenges but also enhance product credibility. Norway's robust healthcare system and emphasis on innovative therapies present significant opportunities for growth in this sector. The country prioritizes research and development, supported by various government initiatives and funding for biotech innovations. The competitive landscape features both established pharmaceutical companies and emerging biotech firms, necessitating thorough market analysis to identify potential collaborators or competitors. Additionally, environmental concerns surrounding biomanufacturing processes should not be overlooked, as sustainability is increasingly becoming a priority in Norway’s industrial practices. Companies must demonstrate responsible sourcing and waste management to align with public expectations and regulatory demands. The global market relevance of bispecific antibodies is also notable, as these therapies are gaining traction in oncology and autoimmune diseases, highlighting the importance of understanding international trends and potential market access challenges. Overall, a comprehensive understanding of these factors is essential for anyone interested in entering the bispecific antibody market in Norway.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | Norway |
| Amount of fitting manufacturers | 26 |
| Amount of suitable service providers | 11 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1988 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Biotechnology, Other, Medical, Healthcare, Consulting
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.